PNU-142633 is an experimental drug candidate for the treatment of migraine. It exerts its effect as a selective, high affinity 5-HT1D receptor antagonist.[1][2] PNU-142633 is well tolerated after oral administration.[3]
Names | |
---|---|
Preferred IUPAC name
(1S)-1-{2-[4-(4-Carbamoylphenyl)piperazin-1-yl]ethyl}-N-methyl-3,4-dihydro-1H-2-benzopyran-6-carboxamide | |
Other names
PNU-142633F
| |
Identifiers | |
| |
3D model (JSmol)
|
|
ChemSpider |
|
PubChem CID
|
|
UNII |
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C24H30N4O3 | |
Molar mass | 422.529 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
|
It was an interesting candidate due to its greater affinity for 5-HT1D compared to 5-HT1B receptors (typical migraine drugs such as triptans are agonists for both receptors), but experimental results were disappointing.[4]
The structure can be compared favorably with Sonepiprazole.
{{cite book}}
: CS1 maint: location missing publisher (link) CS1 maint: others (link)